{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:21:01Z","timestamp":1793762461861,"version":"4.6.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000971","name":"ALS Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000971","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.eclinm.2022.101590","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T02:55:18Z","timestamp":1659581718000},"page":"101590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1914-5061","authenticated-orcid":false,"given":"Benjamin Rix","family":"Brooks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Ciepielewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Suarez","family":"Zambrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Hagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2022.101590_bib0001","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/21678421.2021.1949021","article-title":"Prevalence of amyotrophic lateral sclerosis (ALS), United States, 2016","volume":"23","author":"Mehta","year":"2022","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1016\/j.eclinm.2022.101590_bib0002","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/21678421.2019.1612435","article-title":"Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010\u20132015","volume":"20","author":"Raymond","year":"2019","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1016\/j.eclinm.2022.101590_bib0003","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1212\/WNL.0000000000011396","article-title":"Comparison of phenotypic characteristics and prognosis between black and white patients in a tertiary ALS clinic","volume":"96","author":"Brand","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.eclinm.2022.101590_bib0004","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/21678421.2019.1682614","article-title":"Atlanta metropolitan area amyotrophic lateral sclerosis (ALS) surveillance: incidence and prevalence 2009\u20132011 and survival characteristics through 2015","volume":"21","author":"Punjani","year":"2020","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1016\/j.eclinm.2022.101590_bib0005","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","article-title":"Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial","volume":"16","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.eclinm.2022.101590_bib0006","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/pds.4297","article-title":"Good practices for real-world data studies of treatment and\/or comparative effectiveness: recommendations from the joint ISPOR-ISPE special task force on real-world evidence in health care decision making","volume":"26","author":"Berger","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.eclinm.2022.101590_bib0007","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/cpt.1658","article-title":"Examining the use of real-world evidence in the regulatory process","volume":"107","author":"Beaulieu-Jones","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.eclinm.2022.101590_bib0008","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1161\/CIRCULATIONAHA.120.051718","article-title":"Emulating randomized clinical trials with nonrandomized real-world evidence studies: first results from the RCT DUPLICATE Initiative","volume":"143","author":"Franklin","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.eclinm.2022.101590_bib0009","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1158\/1078-0432.CCR-19-2580","article-title":"FDA approval summary: palbociclib for male patients with metastatic breast cancer","volume":"26","author":"Wedam","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2022.101590_bib0010","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jclinepi.2013.01.013","article-title":"Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research","volume":"66","author":"Stuart","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.eclinm.2022.101590_bib0011","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jocn.2021.12.021","article-title":"Cardiovascular comorbidities in amyotrophic lateral sclerosis: a systematic review","volume":"96","author":"Xu","year":"2022","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.eclinm.2022.101590_bib0012","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3390\/brainsci9090223","article-title":"A comprehensive examination of percutaneous endoscopic gastrostomy and its association with amyotrophic lateral sclerosis patient outcomes","volume":"9","author":"Bond","year":"2019","journal-title":"Brain Sci"},{"key":"10.1016\/j.eclinm.2022.101590_bib0013","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.25661","article-title":"Effect of high-caloric nutrition on survival in amyotrophic lateral sclerosis","volume":"87","author":"Ludolph","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.eclinm.2022.101590_bib0014","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/jnnp-2014-310055","article-title":"Identifying who will benefit from non-invasive ventilation in amyotrophic lateral sclerosis\/motor neurone disease in a clinical cohort","volume":"87","author":"Berlowitz","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.eclinm.2022.101590_bib0015","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12890-016-0297-y","article-title":"Hospitalizations due to respiratory failure in patients with amyotrophic lateral sclerosis and their impact on survival: a population-based cohort study","volume":"16","author":"Pisa","year":"2016","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.eclinm.2022.101590_bib0016","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1471-2377-13-160","article-title":"Diagnosis pathway for patients with amyotrophic lateral sclerosis: retrospective analysis of the US Medicare longitudinal claims database","volume":"13","author":"Williams","year":"2013","journal-title":"BMC Neurol"},{"key":"10.1016\/j.eclinm.2022.101590_bib0017","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1002\/sim.8171","article-title":"Nonproportional hazards and unobserved heterogeneity in clustered survival data: when can we tell the difference?","volume":"38","author":"Balan","year":"2019","journal-title":"Stat Med"},{"key":"10.1016\/j.eclinm.2022.101590_bib0018","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1002\/sim.6274","article-title":"Relaxing the independent censoring assumption in the Cox proportional hazards model using multiple imputation","volume":"33","author":"Jackson","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.eclinm.2022.101590_bib0019","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/bimj.201100042","article-title":"Sensitivity analysis for causal inference using inverse probability weighting","volume":"53","author":"Shen","year":"2011","journal-title":"Biom J"},{"key":"10.1016\/j.eclinm.2022.101590_bib0020","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/21678421.2020.1771734","article-title":"Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis","volume":"21","author":"Andrews","year":"2020","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1016\/j.eclinm.2022.101590_bib0021","article-title":"Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND)","volume":"3","author":"Miller","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eclinm.2022.101590_bib0022","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.14645","article-title":"Assessment of use and safety of edaravone for amyotrophic lateral sclerosis in the Veterans Affairs health care system","volume":"3","author":"Vu","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eclinm.2022.101590_bib0023","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1007\/s00415-020-09993-z","article-title":"The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis","volume":"267","author":"Lunetta","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.eclinm.2022.101590_bib0024","article-title":"Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis","volume":"3","author":"Witzel","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eclinm.2022.101590_bib0025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2188\/jea.JE20120119","article-title":"Riluzole and prognostic factors in amyotrophic lateral sclerosis long-term and short-term survival: a population-based study of 1149 cases in Taiwan","volume":"23","author":"Lee","year":"2013","journal-title":"J Epidemiol"},{"key":"10.1016\/j.eclinm.2022.101590_bib0026","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000369813","article-title":"Epidemiology of amyotrophic lateral sclerosis and effect of riluzole on disease course","volume":"44","author":"Cetin","year":"2015","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.eclinm.2022.101590_bib0027","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1136\/jnnp-2015-312908","article-title":"A clinical tool for predicting survival in ALS","volume":"87","author":"Knibb","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.eclinm.2022.101590_bib0028","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/jnnp-2018-320211","article-title":"Evidence for a multimodal effect of riluzole in patients with ALS?","volume":"90","author":"de Jongh","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.eclinm.2022.101590_bib0029","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/21678421.2019.1655060","article-title":"Pooled resource open-access ALS clinical trials consortium. Stage-specific riluzole effect in amyotrophic lateral sclerosis: a retrospective study","volume":"21","author":"Thakore","year":"2020","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1016\/j.eclinm.2022.101590_bib0030","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s41593-021-01006-0","article-title":"Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines","volume":"25","author":"Baxi","year":"2022","journal-title":"Nat Neurosci"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537022003200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537022003200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:12:33Z","timestamp":1762888353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537022003200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":30,"alternative-id":["S2589537022003200"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2022.101590","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2022.101590","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101590"}}